# Aeris Capital

> Aeris Capital is a VC fund in Pfaffikon backing Biotechnology and Medical. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Pfaffikon, Switzerland
- Total investments: 22
- Last investment: Jun 2016
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aeris-capital-ag/about/
- Website: http://www.aeris-capital.com

Aeris Capital is a VC fund in Pfaffikon focused on Biotechnology and Medical. Aeris Capital AG is a private equity fund and financial advisor with locations in the United States and Switzerland.

## Contacts

5 contacts available for Aeris Capital. Shizune tracks 1 team members at Aeris Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aeris-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 32% |
| Medical | 6 | 27% |
| Health Care | 6 | 27% |
| Therapeutics | 3 | 14% |
| Mobile | 2 | 9% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 23% |
| Series D | 5 | 23% |
| Series C | 4 | 18% |
| Series B | 3 | 14% |
| Series E | 2 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 36% |
| Germany | 2 | 9% |
| Canada | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| George Rehm | Managing Director | 10 | https://shizune.co/investors/profile/george-rehm |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $17.7M | Series C | Jun 07, 2016 |  |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $23.3M | Series C | May 21, 2015 |  |
| Curetis | Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application.However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases. | $15.9M | Series B | Nov 20, 2014 |  |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $18.3M | Series B | Sep 23, 2014 |  |
| Affimed | At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies. | $15.7M | Series E | Sep 02, 2014 |  |
| Smaato | Smaato’s Digital Advertising Technology Platform gives publishers the controls to deliver seamless, tailored, and engaging experiences for their audiences and advertisers. Advanced targeting capabilities and competitive intelligence help publishers optimize their monetization strategy to create data-driven experiences and reach their full revenuepotential. Founded in 2005, Smaato is headquartered in San Francisco, California, with additional offices in Hamburg, New York, Shanghai, Beijing, and Singapore. Learn more at www.smaato.com. | $25M | Series E | Aug 05, 2014 |  |
| GenomeDx Biosciences | GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine. |  | Series B | Sep 30, 2013 |  |
| Solstice Biologics | Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.It was established in 2012 and is based in SanFrancisco, California. | $18M | Series A | Jan 04, 2013 |  |
| Crescendo Bioscience | Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory diseases. It provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians. Crescendo Bioscience, Inc. was formerly known asRiley Genomics, Inc. The company was founded in 2002 and is based in South San Francisco, California. | $28M | Series D | Jan 03, 2013 |  |
| Solstice Biologics | Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.It was established in 2012 and is based in SanFrancisco, California. | $7.5M | Private Equity | Dec 28, 2012 |  |

10 of 22 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 6 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 4 deals together
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 3 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 3 deals together
- [Mohr Davidow Ventures](https://shizune.co/investors/profile/mohr-davidow-ventures) — VC Fund, 3 deals together
- [Baird Capital](https://shizune.co/investors/profile/baird-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)

## FAQ

### What does Aeris Capital invest in?

Aeris Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series D stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aeris Capital?

Public channels for Aeris Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aeris Capital?

The team at Aeris Capital includes George Rehm (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co